Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. Beyond the Androgen Receptor

Urologic Clinics of North America

Volumn 39, Issue 4, 2012, Pages 517-531

  Loriot, Yohann ^a   Zoubeidi, Amina ^a   Gleave, Martin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cabazitaxel; Cabozantinib; Clusterin; Dasatinib; Hsp27; OGX 011; Prostate cancer

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; DASATINIB; DOCETAXEL; ENZALUTAMIDE; EPOTHILONE B; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; ISOSORBIDE; IXABEPILONE; MITOXANTRONE; NAVITOCLAX; OBLIMERSEN; OGX 427; OLAPARIB; PLACEBO; PLATINUM COMPLEX; PREDNISONE; PROTEIN BCL 2; SAGOPILONE; SARACATINIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHILL; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CONTINUOUS INFUSION; DECREASED APPETITE; DIARRHEA; DNA REPAIR; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FUSION GENE; GASTROINTESTINAL SYMPTOM; GENE FUSION; GLIOMA; HAIR LOSS; HUMAN; KIDNEY CARCINOMA; LOADING DRUG DOSE; LUNG CANCER; LUNG TUMOR; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SOLID TUMOR; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

BONE NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; DNA REPAIR; EPOTHILONES; GENE FUSION; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; PYRIMIDINES; RECEPTORS, ANDROGEN; TAXOIDS; THIAZOLES;

EID: 84867670047     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2012.07.008     Document Type: Review

References (118)

1. La Vecchia C., Bosetti C., Lucchini F., et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010, 21:1323-1360.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
3. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N Engl J Med 2003, 349:366-381.
4. Attard G., Sarker D., Reid A., et al. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006, 95:767-774.
5. Chen Y., Clegg N.J., Scher H.I. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009, 10:981-991.
6. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008, 26:4563-4571.
7. Scher H.I., Beer T.M., Higano C.S., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
8. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
9. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010, 10:194-204.
10. Darshan M.S., Loftus M.S., Thadani-Mulero M., et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011, 71:6019-6029.
11. Zhu M.L., Horbinski C.M., Garzotto M., et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010, 70:7992-8002.
12. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
13. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
14. Seruga B., Tannock I.F. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 2011, 29:3686-3694.
15. Marín-Aguilera M., Codony-Servat J., Kalko S.G., et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 2012, 11:329-339.
16. Al Nakouzi N., Gaudin C., Delbruel L., et al. Molecular determinants of docetaxel-resistance in prostate cancer cells. AACR Meeting Abstracts 2009, 2009:2944.
17. Mita A.C., Denis L.J., Rowinsky E.K., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15:723-730.
18. Pivot X., Koralewski P., Hidalgo J.L., et al. A multicenter phase II study of XRP6258 administered as a 1-h I.V. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008, 19:1547-1552.
19. de Bono J.S., Oudard S., Ozguroglu M., TROPIC Investigators, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
20. Lee J.J., Kelly W.K. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol 2009, 6:85-92.
21. Orr G.A., Verdier-Pinard P., McDaid H., et al. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22:7280-7295.
22. Altmann K.H., Wartmann M., O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000, 1470:M79-M91.
23. O'Reilly T., McSheehy P.M., Wenger F., et al. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate 2005, 65:231-240.
24. Chou T.C., Dong H., Zhang X., et al. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route. Cancer Res 2005, 65:9445-9454.
25. Pivot X., Dufresne A., Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer 2007, 7:543-549.
26. Hoffmann J., Vitale I., Buchmann B., et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008, 68:5301-5308.
27. Galsky M.D., Small E.J., Oh W.K., et al. Multi-national randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005, 23:1439-1446.
28. Hussain M., Tangen C.M., Lara P.N., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group Trial S0111. J Clin Oncol 2005, 23:8724-8729.
29. Rosenberg J.E., Ryan C.J., Weinberg V.K., et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009, 27:2772-2778.
30. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007, 110:556-563.
31. Harzstark A.L., Rosenberg J.E., Weinberg V.K., et al. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer 2011, 117:2419-2425.
32. Chi K.N., Beardsley E., Eigl B.J., et al. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol 2012, 23:53-58.
33. Graff J., Smith D.C., Neerkonch L., et al. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol 2008, 26(May 20 Suppl):5141. [abstract].
34. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
35. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
36. Gelmon K.A., Tischkowitz M., Mackay H., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12:852-861.
37. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
38. Kamal N.S., Soria J.C., Mendiboure J., International Adjuvant Lung Trial-Bio Investigators, et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010, 16:1206-1215.
39. Bellmunt J., Paz-Ares L., Cuello M., et al. ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18:522-528.
40. Kote-Jarai Z., Leongamornlert D., Saunders E., et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011, 105:1230-1234.
41. Gallagher D.J., Gaudet M.M., Pal P., et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010, 16:2115-2121.
42. Nakabayashi M., Sartor O., Jacobus S., et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 2008, 101:308-312.
43. Ross R.W., Beer T.M., Jacobus S., Prostate Cancer Clinical Trials Consortium, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008, 112:521-526.
44. Sternberg C.N., Petrylak D.P., Sartor O., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009, 27:5431-5438.
45. Loriot Y., Massard C., Gross-Goupil M., et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009, 20:703-708.
46. Gallagher D.J., Cronin A.M., Milowsky M.I., et al. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int 2012, 109:713-719.
47. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
48. King J.C., Xu J., Wongvipat J., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009, 41:524-526.
49. Haffner M.C., Aryee M.J., Toubaji A., et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010, 42:668-675.
50. Brenner J.C., Ateeq B., Li Y., et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011, 19:664-678.
51. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
52. Hussain M., Carducci M.A., Slovin S.F., et al. Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012, 30(Suppl 5). [abstract: 224].
53. Galluzzi L., Larochette N., Zamzami N., et al. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
54. McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52:6940-6944.
55. Banerjee D. Technology evaluation: G-3139. Curr Opin Mol Ther 1999, 1:404-408.
56. Benimetskaya L., Miller P., Benimetsky S., et al. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol Pharmacol 2001, 60:1296-1307.
57. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
58. Bray K., Chen H.Y., Karp C.M., et al. Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res 2009, 7:1487-1496.
59. Tolcher A.W., Kuhn J., Schwartz G., et al. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004, 10:5048-5057.
60. Sternberg C.N., Dumez H., Van Poppel H., et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009, 20:1264-1269.
61. Liu G., Kelly W.K., Wilding G., et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009, 15:3172-3176.
62. Sonpavde G., Matveev V., Burke J.M., et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 2012, 23:1803-1808.
63. Rocchi P., So A., Kojima S., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004, 64:6595-6602.
64. Miyake H., Nelson C., Rennie P.S., et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000, 60:170-176.
65. Gleave M., Miyake H., Zangemeister-Wittke U., et al. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev 2002, 21:79-92.
66. Zellweger T., Miyake H., July L.V., et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001, 3:360-367.
67. Carver J.A., Rekas A., Thorn D.C., et al. Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function?. IUBMB Life 2003, 55:661-668.
68. Nizard P., Tetley S., Le Drean Y., et al. Stress-induced retrotranslocation of clusterin/ApoJ into the cytosol. Traffic 2007, 8:554-565.
69. Steinberg J., Oyasu R., Lang S., et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997, 3:1707-1711.
70. July L.V., Akbari M., Zellweger T., et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002, 50:179-188.
71. Song H., Zhang B., Watson M.A., et al. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009, 28:3307-3319.
72. Sowery R.D., Hadaschik B.A., So A.I., et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008, 102:389-397.
73. Gleave M., Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005, 23:38-46.
74. Chi K.N., Eisenhauer E., Fazli L., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005, 97:1287-1296.
75. Chi K.N., Siu L.L., Hirte H., et al. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008, 14:833-839.
76. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
77. Chi K.N., Hotte S.J., Yu E.Y., et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:4247-4254.
78. Saad F., Hotte S., North S. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011, 17:5765-5773.
79. Zoubeidi A., Zardan A., Beraldi E., et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007, 67:10455-10465.
80. Zoubeidi A., Zardan A., Wiedmann R.M., et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 2010, 70:2307-2317. [Erratum appears in Cancer Res 2011;71:5054].
81. Kato K., Tokuda H., Mizutani J., et al. Role of HSP27 in tumor necrosis factor-α-stimulated interleukin-6 synthesis in osteoblasts. Int J Mol Med 2011, 28:887-893.
82. Cornford P.A., Dodson A.R., Parsons K.F., et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000, 60:7099.
83. Rocchi P., Jugpal P., So A., et al. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 2006, 98:1082-1089.
84. Andrieu C., Taieb D., Baylot V., et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 2010, 29:1883-1896.
85. Hotte S.J., Yu E.Y., Hirte H.Y., et al. Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): final results. J Clin Oncol 2010, 28(Suppl):15s. [abstract: 3077].
86. Chi K.N., Hotte S.J., Ellard S., et al. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. J Clin Oncol 2012, 30(Suppl 5). [abstract: 121].
87. Cecchi F., Rabe D.C., Bottaro D.P. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010, 46:1260-1270.
88. Davies G., Watkins G., Mason M.D., et al. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells. Prostate 2004, 60:317-324.
89. Verras M., Lee J., Xue H., et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007, 67:967-975.
90. Humphrey P.A., Zhu X., Zarnegar R., et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995, 147:386-396.
91. Gupta A., Karakiewicz P.I., Roehrborn C.G., et al. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res 2008, 14:7385-7390.
92. Yasuda K., Nagakawa O., Akashi T., et al. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate 2009, 69:346-351.
93. Dai Y., Siemann D.W. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 2010, 9:1554-1561.
94. Yakes F.M., Chen J., Tan J., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011, 10:2298-2308.
95. Tu W.H., Zhu C., Clark C., et al. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 2010, 10:556.
96. Salgia R, Hong S, Sherman S, et al. A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, October 22-26, 2007, A152.
97. Hussain M., Smith M.R., Sweeney C., et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol 2011, 29(Suppl). [abstract: 4516].
98. Saylor P.J., Lee R.J., Smith M.R. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 2011, 29:3705-3714.
99. Asim M., Siddiqui I.A., Hafeez B.B., et al. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 2008, 27:3596-3604.
100. Cai H., Babic I., Wei X., et al. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res 2011, 71:862-872.
101. Efstathiou E., Titus M.A., Tsavachidou D., et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report. J Clin Oncol 2011, 29(Suppl). [abstract: 4501].
102. Rice L., Lepler S., Pampo C., et al. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis 2012, 29:133-142.
103. Cai H., Smith D.A., Memarzadeh S., et al. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci U S A 2011, 108:6579-6584.
104. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
105. Tatarov O., Mitchell T.J., Seywright M., et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009, 15:3540-3549.
106. Park S.I., Zhang J., Phillips K.A., et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008, 68:3323-3333.
107. Koreckij T., Nguyen H., Brown L.G., et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Br J Cancer 2009, 101:263-268.
108. Dayyani F., Parikh N., Song J.H., et al. Effect of dual inhibition of the Src and insulin-like growth factor-1 receptor (IGF-1R) pathways on antitumor effects in prostate cancer (PCa). J Clin Oncol 2011, 29(Suppl). [abstract: e15004].
109. Hennequin L.F., Allen J., Breed J., et al. N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006, 49:6465-6488.
110. de Vries T.J., Mullender M.G., van Duin M.A., et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 2009, 7:476-488.
111. Yang J.C., Bai L., Yap S., et al. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther 2010, 9:1629-1637.
112. Yang J.C., Ok J.H., Busby J.E., et al. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009, 69:151-160.
113. Chang Y.M., Bai L., Liu S., et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 27:6365-6375.
114. Yu E.Y., Wilding G., Posadas E., et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009, 15:7421-7428.
115. Yu E.Y., Massard C., Gross M.E., et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011, 77:1166-1171.
116. Araujo J.C., Mathew P., Armstrong A.J., et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012, 118:63-71.
117. Twardowski, Chen C., Kraft A.S., et al. A phase II trial of dasatinib in subjects with hormone-refractory prostate cancer previously treated with chemotherapy. J Clin Oncol 2011, 29(Suppl). [abstract: 4575].
118. Baselga J., Cervantes A., Martinelli E., et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010, 16:4876-4883.